Increased cannabis intake during the COVID-19 pandemic is associated with worsening of depression symptoms in people with PTSD A. Murkar, T. Kendzerska, J. Shlik, L. Quilty, M. Saad and R. Robillard BMC Psychiatry, 2022, 22, 554 Doi : 10.1186/s12888-022-04185-7 Abstract Background: Some evidence suggests substance use affects clinical outcomes in people with posttraumatic stress disorder (PTSD). However, more work is required to examine links between mental health and cannabis use in PTSD during exposure to external stressors such as the COVID-19 pandemic. This study assessed mental health factors in individuals with self-reported PTSD to: (a) determine whether stress, anxiety, and depression symptoms were associ- ated with changes [...]
Lire la suitePsychedelic science in post-COVID-19 psychiatry J. R. Kelly, M. T. Crockett, L. Alexander, M. Haran, A. Baker, L. Burke, C. Brennan and V. O’Keane Irish Journal of Psychological Medicine, 2020, 1-6. doi:10.1017/ipm.2020.94 The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are pre- dicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition [...]
Lire la suiteCannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants Richard B. van Breemen, Ruth N. Muchiri, Timothy A. Bates, Jules B. Weinstein, Hans C. Leier, Scotland Farley, and Fikadu G. Tafesse Journal of Natural Products, 2022, 85, 176−184. Doi : 10.1021/acs.jnatprod.1c00946 ABSTRACT : As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection−mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands [...]
Lire la suiteNational Retail Sales of Alcohol and Cannabis During the COVID-19 Pandemic in Canada James MacKillop, PhD; Alysha Cooper, MSc; Jean Costello, PhD JAMA Network Open, 2021, 4, (11), e2133076, 1-4. Doi : 10.1001/jamanetworkopen.2021.33076 Introduction There is concern that the societal consequences of the COVID-19 pandemic will be associated with increased substance use.1 Data to date have primarily been self-reported changes, but objective sales data may inform this question. Here, we examined national retail sales of alcohol and cannabis prior to and during the pandemic in Canada. Methods : Where applicable, the report for this economic evaluation is consistent with the Consolidated Health Economic Evaluation Reporting Standards [...]
Lire la suiteEfficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health CareWorkers During the COVID-19 Pandemic. A Randomized Clinical Trial José Alexandre S. Crippa, PhD; AntonioW. Zuardi, PhD; Francisco S. Guimarães, PhD; Alline Cristina Campos, PhD; Flávia de Lima Osório, PhD; Sonia Regina Loureiro, PhD; Rafael G. dos Santos, PhD; José Diogo S. Souza, MD; Juliana Mayumi Ushirohira, MD, MSc; Julia Cozar Pacheco, RPh; Rafael Rinaldi Ferreira, PhD, RPh; Karla Cristinne Mancini Costa, MSc; Davi Silveira Scomparin, MSc; Franciele Franco Scarante, MSc; Isabela Pires-Dos-Santos, VMD; Raphael Mechoulam, PhD; Flávio Kapczinski, PhD; Benedito [...]
Lire la suiteEntre confinement et répression : comment les usagers de cannabis se sont organisés Raphaël Carrez & Fabienne Lopez Psychotropes, 2020, 26, (2-3), 165-1783. Introduction L’association Principes Actifs milite pour la reconnaissance légale de l’usage thérapeutique du cannabis en France depuis sa création en 2009. Nous fournissons conseils et informations aux personnes atteintes d’affections diverses qui nous contactent. En 2014, nous avons mis en place des « ateliers de réduction des risques cannabis » à destination des structures d’addictologie, des professionnels de santé et des associations de patients, afin de présenter l’usage thérapeutique dans toutes ses spécificités. L’association participe depuis fin 2019 au comité de pilotage instauré par [...]
Lire la suiteFlash info 19/11/2020 MILDECA Covid-19 : isolement et conditions de travail favorisent les conduites addictives Depuis le premier confinement instauré en mars dernier, l’isolement au travail, l’augmentation des objectifs en matière de performance ainsi que la charge de travail ont joué un rôle dans l’augmentation des consommations de substances psychoactives. C’est ce que montre l’enquête publiée ce jour par la MILDECA et ses partenaires. Pour documenter l’évolution des consommations de substances psychoactives et les conditions de travail en période d’épidémie de Covid-19, la MILDECA et ses partenaires - ANSES, Anact, INRS, OFDT, Santé Publique France et le COCT * - ont commandité une enquête [...]
Lire la suiteHow Cannabis-Based Therapeutics Could Help Fight COVID Inflammation Liz Scherer Medscape.com, November 03, 2020 Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Plagued by false starts, a few dashed hopes, but with perhaps a glimmer of light on the horizon, the race to find an effective treatment for COVID-19 continues. At last count, more than 300 treatments and 200 vaccines were in preclinical or clinical development (not to mention the numerous existing agents that are being evaluated for repurposing). There is also a renewed interest in cannabinoid therapeutics — in particular, the nonpsychoactive agent cannabidiol (CBD) and the prospect of [...]
Lire la suiteFDA Approves Clinical Trials for Cannabinoid Drug Designed to Reduce COVID Lung Inflammation Ralph Ellis Medscape, August 21, 2020 The US Food and Drug Administration has approved phase one clinical trials for a synthetic cannabinoid drug designed to treat acute respiratory distress syndrome (ARDS), a life-threatening lung condition which may occur in severe cases of the novel coronavirus, Forbes reported. ARDS can be triggered by over-creation of cytokines, proteins which tell the body to produce more inflammation, Forbes said. The drug going to clinical trials, ARDS-003, would “dampen the cytokine release" and prevent development of ARDS, Tetra Bio-Pharma company CEO and chief regulatory officer Guy Chamberland, MD, [...]
Lire la suiteTRIBUNE. « Après la crise du Covid-19, il faut légaliser le cannabis, vite ! » Emmenés par le député des Bouches-du-Rhône François-Michel Lambert, une soixantaine d’élus de tous bords (LREM, EELV, UDI, LFI, LR) et des médecins estiment que la légalisation du cannabis est une des solutions du monde d’après Covid-19 Par François-Michel Lambert (député et coprésident de LEF), Caroline Janvier (députée LREM), Sylvia Pinel (députée PRG) et Jean-Luc Bennahmias (membre du CESE) Publié le 18 juin 2020 à 07h00 Mis à jour le 18 juin 2020 à 19h31 https://www.nouvelobs.com/societe/20200618.OBS30192/tribune-apres-la-crise-du-covid-19-il-faut-legaliser-le-cannabis-vite.html#modal-msg Photo d’illustration. (ROBYN BECK / AFP) En juin 2019, avec une vingtaine de députés, nous déposions une proposition de [...]
Lire la suite